Yes - Jon says that the trofinetide success was "just the start"....
And he is much more upbeat about NNZ-2591 - he initiated the captial raising last year in the off chance that the phase 3 trofinetide trials failed.
In hindsight - that was not necessary.
This is the statement that encourages me the most about Neuren...from Jon Pilcher himself...
Yes trofinetide and NNZ-2591 both originate from Dame Margaret Brimble's work in Auckland. They are analogs of two different molecules - glycine proline glutamate (GPE) and cyclic glycine proline (cGP) respectively. Each plays a role in the metabolism of IGF-1 in the brain. The desired outcome of using the power of IGF-1 in the brain is the same, but with a different mechanism to achieve it. They also have different properties as drugs, with 2591 clearly superior in a few ways.
GLTAH - 2022 with our 2 drugs this is going 2 be our year!
Focus now on NNZ2591, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.18 |
Change
-0.430(3.16%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $13.64 | $13.67 | $13.18 | $8.868M | 666.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5233 | $13.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |